{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:04:27Z","timestamp":1772255067519,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Little is known about the association between plasma adiponectin levels and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). We examined whether there is an association between lower plasma adiponectin levels and the presence\/severity of NAFLD in people with T2DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We cross-sectionally recruited 79 men with non-insulin-treated T2DM and no known liver diseases, who had consecutively attended our diabetes outpatient service over a 6-month period and who underwent both ultrasonography and Fibroscan-measured liver stiffness (LSM). Nine single nucleotide polymorphisms (<jats:italic>PNPLA3<\/jats:italic> rs738409 and other genetic variants) associated with NAFLD were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 79 participants included (mean age 67\u2009\u00b1\u200910\u00a0years, BMI 27.7\u2009\u00b1\u20094\u00a0kg\/m<jats:sup>2<\/jats:sup>), 28 did not have NAFLD, 32 had steatosis alone, and 19 had NAFLD with coexisting significant fibrosis (LSM\u2009\u2265\u20097.0\u00a0kPa by Fibroscan\u00ae). Compared to those without NAFLD, patients with hepatic steatosis alone and those with hepatic steatosis and coexisting significant fibrosis had lower high-molecular-weight adiponectin levels (5.5 [IQR 2.3\u20137.6] <jats:italic>vs<\/jats:italic>. 2.4 [1.8\u20133.7] vs. 1.6 [1.0\u20132.9] \u00b5g\/mL; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). After adjustment for age, body mass index, insulin resistance, and the <jats:italic>PNPLA3<\/jats:italic> rs738409 variant, lower plasma adiponectin levels were found to be associated with increased odds of both steatosis alone (adjusted-odds ratio [OR] 2.44, 95% CI 1.04\u20135.56, <jats:italic>p<\/jats:italic>\u2009=\u20090.042) and NAFLD with coexisting significant fibrosis (adjusted-OR 3.84, 95% CI 1.23\u201310.0, <jats:italic>p<\/jats:italic>\u2009=\u20090.020). Similar findings were observed after adjustment for the other eight genotyped NAFLD-related polymorphisms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Lower plasma adiponectin levels are closely associated with the presence and severity of NAFLD in men with T2DM, pointing to a role of adiponectin in NAFLD development and progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s42000-022-00387-6","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:04:37Z","timestamp":1657753477000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study"],"prefix":"10.1007","volume":"21","author":[{"given":"Alessandro","family":"Mantovani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Zusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Csermely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luca","family":"Salvagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"387_CR1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"387_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328\u2013357","journal-title":"Hepatology"},{"key":"387_CR3","doi-asserted-by":"crossref","unstructured":"Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021.","DOI":"10.1016\/j.cgh.2021.12.002"},{"key":"387_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399:61\u2013116","journal-title":"Lancet"},{"key":"387_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71:793\u2013801","journal-title":"J Hepatol"},{"key":"387_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S et al (2020) Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 19:359\u2013366","journal-title":"Ann Hepatol"},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A et al (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S:154170","journal-title":"Metabolism"},{"key":"387_CR8","doi-asserted-by":"publisher","first-page":"154028","DOI":"10.1016\/j.metabol.2019.154028","volume":"103","author":"C Boutari","year":"2020","unstructured":"Boutari C, Mantzoros CS (2020) Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 103:154028","journal-title":"Metabolism"},{"key":"387_CR9","doi-asserted-by":"publisher","first-page":"110785","DOI":"10.1016\/j.biopha.2020.110785","volume":"131","author":"SC Shabalala","year":"2020","unstructured":"Shabalala SC, Dludla PV, Mabasa L et al (2020) The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother 131:110785","journal-title":"Biomed Pharmacother"},{"key":"387_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/ijms21041219","volume":"21","author":"HM Choi","year":"2020","unstructured":"Choi HM, Doss HM, Kim KS (2020) Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci 21:1219","journal-title":"Int J Mol Sci"},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"e23148","DOI":"10.1002\/jcla.23148","volume":"34","author":"K Lian","year":"2020","unstructured":"Lian K, Feng YN, Li R et al (2020) Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease. J Clin Lab Anal 34:e23148","journal-title":"J Clin Lab Anal"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"154026","DOI":"10.1016\/j.metabol.2019.154026","volume":"103","author":"YS Kim","year":"2020","unstructured":"Kim YS, Lee SH, Park SG et al (2020) Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 103:154026","journal-title":"Metabolism"},{"key":"387_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/1751-2980.12980","volume":"22","author":"MG Mavilia","year":"2021","unstructured":"Mavilia MG, Wu GY (2021) Liver and serum adiponectin levels in non-alcoholic fatty liver disease. J Dig Dis 22:214\u2013221","journal-title":"J Dig Dis"},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"683250","DOI":"10.3389\/fmed.2021.683250","volume":"8","author":"V Marques","year":"2021","unstructured":"Marques V, Afonso MB, Bierig N et al (2021) Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD. Front Med (Lausanne) 8:683250","journal-title":"Front Med (Lausanne)"},{"key":"387_CR15","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1111\/liv.15005","volume":"41","author":"A Gastaldelli","year":"2021","unstructured":"Gastaldelli A, Sabatini S, Carli F et al (2021) PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int 41:2659\u20132670","journal-title":"Liver Int"},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","volume":"56","author":"S Zelber-Sagi","year":"2012","unstructured":"Zelber-Sagi S, Lotan R, Shlomai A et al (2012) Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 56:1145\u20131151","journal-title":"J Hepatol"},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","volume":"60","author":"SA Polyzos","year":"2011","unstructured":"Polyzos SA, Toulis KA, Goulis DG et al (2011) Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60:313\u2013326","journal-title":"Metabolism"},{"key":"387_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1872-034X.2012.01106.x","volume":"43","author":"NC Leite","year":"2013","unstructured":"Leite NC, Salles GF, Cardoso CR et al (2013) Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 43:508\u2013515","journal-title":"Hepatol Res"},{"key":"387_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 68:268\u2013279","journal-title":"J Hepatol"},{"key":"387_CR20","doi-asserted-by":"publisher","first-page":"e00179","DOI":"10.1002\/edm2.179","volume":"3","author":"F Tavaglione","year":"2020","unstructured":"Tavaglione F, Targher G, Valenti L et al (2020) Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 3:e00179","journal-title":"Endocrinol Diabetes Metab"},{"key":"387_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40618-020-01340-3","volume":"44","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Danese E, Salvagno GL et al (2021) Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. J Endocrinol Invest 44:547\u2013555","journal-title":"J Endocrinol Invest"},{"key":"387_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Turino T, Lando MG et al (2020) Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab 46:296\u2013303","journal-title":"Diabetes Metab"},{"key":"387_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487\u20131495","journal-title":"Diabetes Care"},{"key":"387_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"387_CR25","doi-asserted-by":"publisher","first-page":"k2734","DOI":"10.1136\/bmj.k2734","volume":"362","author":"CD Byrne","year":"2018","unstructured":"Byrne CD, Patel J, Scorletti E et al (2018) Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ 362:k2734","journal-title":"BMJ"},{"key":"387_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","volume":"72","author":"S Ballestri","year":"2017","unstructured":"Ballestri S, Nascimbeni F, Baldelli E et al (2017) Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases. Metabolism 72:57\u201365","journal-title":"Metabolism"},{"key":"387_CR27","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/jgh.13762","volume":"32","author":"M Puigvehi","year":"2017","unstructured":"Puigvehi M, Broquetas T, Coll S et al (2017) Impact of anthropometric features on the applicability and accuracy of FibroScan((R)) (M and XL) in overweight\/obese patients. J Gastroenterol Hepatol 32:1746\u20131753","journal-title":"J Gastroenterol Hepatol"},{"key":"387_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11154-019-09510-2","volume":"20","author":"SM Ishtiaq","year":"2019","unstructured":"Ishtiaq SM, Rashid H, Hussain Z et al (2019) Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease. Rev Endocr Metab Disord 20:253\u2013261","journal-title":"Rev Endocr Metab Disord"},{"key":"387_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/CS20100008","volume":"119","author":"ML Balmer","year":"2010","unstructured":"Balmer ML, Joneli J, Schoepfer A et al (2010) Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) 119:431\u2013436","journal-title":"Clin Sci (Lond)"},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"798417","DOI":"10.3389\/fendo.2022.798417","volume":"13","author":"YT Zheng","year":"2022","unstructured":"Zheng YT, Xiao TM, Wu CX et al (2022) Correlation of adiponectin gene polymorphisms rs266729 and rs3774261 with risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:798417","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1264\u201381","key":"387_CR31","first-page":"e4","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(1264\u201381):e4","journal-title":"Gastroenterology"},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-230X-12-111","volume":"12","author":"L Valenti","year":"2012","unstructured":"Valenti L, Rametta R, Ruscica M et al (2012) The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 12:111","journal-title":"BMC Gastroenterol"},{"key":"387_CR33","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","volume":"55","author":"AT Turer","year":"2012","unstructured":"Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55:2319\u20132326","journal-title":"Diabetologia"},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nm1557","volume":"13","author":"T Yamauchi","year":"2007","unstructured":"Yamauchi T, Nio Y, Maki T et al (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332\u2013339","journal-title":"Nat Med"},{"key":"387_CR35","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1038\/s41467-020-19668-y","volume":"11","author":"H Xu","year":"2020","unstructured":"Xu H, Zhao Q, Song N et al (2020) AdipoR1\/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. Nat Commun 11:5807","journal-title":"Nat Commun"},{"key":"387_CR36","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00109-015-1313-z","volume":"93","author":"Z Dong","year":"2015","unstructured":"Dong Z, Su L, Esmaili S et al (2015) Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J Mol Med (Berl) 93:1327\u20131339","journal-title":"J Mol Med (Berl)"},{"key":"387_CR37","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1074\/jbc.M114.598011","volume":"290","author":"M Ramezani-Moghadam","year":"2015","unstructured":"Ramezani-Moghadam M, Wang J, Ho V et al (2015) Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion. J Biol Chem 290:5533\u20135542","journal-title":"J Biol Chem"},{"key":"387_CR38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbadis.2017.12.012","volume":"1864","author":"B Alzahrani","year":"2018","unstructured":"Alzahrani B, Iseli T, Ramezani-Moghadam M et al (2018) The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochim Biophys Acta Mol Basis Dis 1864:700\u2013708","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"387_CR39","doi-asserted-by":"crossref","unstructured":"Mantovani A, Byrne CD, Targher G. (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol","DOI":"10.1016\/S2468-1253(21)00261-2"},{"key":"387_CR40","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Mantzoros CS (2016) Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism 65:1297\u20131306","journal-title":"Metabolism"},{"key":"387_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.metabol.2018.10.004","volume":"90","author":"A Ahmad","year":"2019","unstructured":"Ahmad A, Ali T, Kim MW et al (2019) Adiponectin homolog novel osmotin protects obesity\/diabetes-induced NAFLD by upregulating AdipoRs\/PPARalpha signaling in ob\/ob and db\/db transgenic mouse models. Metabolism 90:31\u201343","journal-title":"Metabolism"},{"key":"387_CR42","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2337\/dc13-2480","volume":"37","author":"AM DePaoli","year":"2014","unstructured":"DePaoli AM, Higgins LS, Henry RR et al (2014) Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37:1918\u20131923","journal-title":"Diabetes Care"},{"key":"387_CR43","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S et al (2019) Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70:1457\u20131469","journal-title":"Hepatology"},{"key":"387_CR44","first-page":"7","volume":"1","author":"S Ballestri","year":"2021","unstructured":"Ballestri S, Mantovani A, Byrne CD et al (2021) Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage 1:7","journal-title":"Metab Target Organ Damage"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-022-00387-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-022-00387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:22:01Z","timestamp":1662949321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-022-00387-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s42000-022-00387-6","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"18 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of the study was approved by the local Ethics Committee of the Hospital Trust of Verona (protocol number: CE 2004CESC), Verona, Italy. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}